| Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study ER Ahn, PK Mangat, E Garrett-Mayer, S Halabi, EG Dib, DE Haggstrom, ... JCO precision oncology 4, 757-766, 2020 | 63 | 2020 |
| Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment E Ramsdale, M Mohamed, V Yu, E Otto, K Juba, H Awad, K Moorthi, ... The oncologist 27 (7), e580-e588, 2022 | 42 | 2022 |
| Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy. EG Dib, JJ Ifthikharuddin, GA Scott, SR Partilo Leukemia Research 29 (2), 233-234, 2005 | 35 | 2005 |
| Case reports and the fight against cancer EG Dib, MR Kidd, DC Saltman Journal of Medical Case Reports 2, 1-2, 2008 | 27 | 2008 |
| Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell … SF Powell, M Mazurczak, EG Dib, JS Bleeker, LH Geeraerts, M Tinguely, ... Investigational new drugs 40 (3), 622-633, 2022 | 24 | 2022 |
| Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis EG Dib, SA Dib, DA Korkmaz, NK Mobarakai, JB Glaser Emerging Infectious Diseases 9 (8), 1013, 2003 | 24 | 2003 |
| The relationship between frailty and emotional health in older patients with advanced cancer N Gilmore, L Kehoe, J Bauer, H Xu, B Hall, M Wells, L Lei, E Culakova, ... The Oncologist 26 (12), e2181-e2191, 2021 | 21 | 2021 |
| Using geriatric assessment to guide conversations regarding comorbidities among older patients with advanced cancer AS Kleckner, M Wells, LA Kehoe, NJ Gilmore, H Xu, A Magnuson, ... JCO Oncology Practice 18 (1), e9-e19, 2022 | 15 | 2022 |
| Multifocal myoclonus induced by trimethoprim–sulfamethoxazole therapy in a patient with Nocardia infection EG Dib, S Bernstein, C Benesch New England Journal of Medicine 350 (1), 88-89, 2004 | 13 | 2004 |
| Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study ES Yang, S Halabi, M Rothe, E Garrett-Mayer, PK Mangat, E Pisick, E Dib, ... JCO Precision Oncology 7, e2200505, 2023 | 12 | 2023 |
| Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization … ER Ahn, PK Mangat, E Garrett-Mayer, S Halabi, EG Dib, DE Haggstrom, ... Journal of Clinical Oncology 37 (15_suppl), 9041-9041, 2019 | 11 | 2019 |
| Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization … AK Ganti, M Rothe, PK Mangat, E Garrett-Mayer, EG Dib, HL Duvivier, ... JCO Precision Oncology 7, e2300041, 2023 | 9 | 2023 |
| Delivering precision oncology in a community cancer program: results from a prospective observational study SF Powell, EG Dib, JS Bleeker, MD Keppen, M Mazurczak, KM Hack, ... JCO Precision Oncology 2, 1-12, 2018 | 9 | 2018 |
| Alliance A041702: a randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (≥ 70 years of age … J Woyach, AS Ruppert, G Perez, AM Booth, D Feldman, EG Dib, A Jatoi, ... Blood 134, 1751, 2019 | 7 | 2019 |
| Pertuzumab plus trastuzumab (P+ T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the … TL Cannon, M Rothe, E Garrett-Mayer, VK Chiu, JJ Hwang, N Vijayvergia, ... Journal of Clinical Oncology 41 (4_suppl), 546-546, 2023 | 6 | 2023 |
| Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. EP Pisick, E Garrett-Mayer, S Halabi, PK Mangat, ESH Yang, EG Dib, ... Journal of Clinical Oncology 38 (15_suppl), 5567-5567, 2020 | 6 | 2020 |
| Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance). JA Woyach, J Yin, JR Brown, S Dinner, G Lozanski, RF Little, C Miller, ... Journal of Clinical Oncology 41 (16_suppl), 7500-7500, 2023 | 5 | 2023 |
| Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. D Behl, M Rothe, PK Mangat, E Garrett-Mayer, LC Farrington, OV Crysler, ... Journal of Clinical Oncology 41 (4_suppl), 122-122, 2023 | 4 | 2023 |
| Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events. DE Kozono, E Sharon, J Le-Rademacher, E Twohy, TJ Zemla, Y Wen, ... Journal of Clinical Oncology 38 (15_suppl), TPS3154-TPS3154, 2020 | 4 | 2020 |
| A041702: a randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (≥ 70 years of age) with … JA Woyach, AS Ruppert, G Perez, AM Booth, D Feldman, EG Dib, A Jatoi, ... Blood 138, 3728, 2021 | 3 | 2021 |
